Navigation Links
European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed
Date:11/15/2007

COLUMBIA, Md., Nov. 15 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation (Nasdaq: MATK) announced today that the Opposition Division of the European Patent Office (EPO) has ruled in favor of Martek and upheld one of the Company's European docosahexaenoic acid (DHA) patents. The modified claims of the patent are narrower than the claims originally granted but broader than the claims that were previously upheld in a December 2000 Opposition Division hearing. The patent, which expires in November 2010, relates to fermentation processes, human and animal food products, pharmaceutical uses of certain claimed microorganisms, and Martek's food DHA production strain.

Fermentation process claims in the patent that provide important commercial protection for Martek were upheld by the EPO, while certain product claims were narrowed by the elimination of coverage for extracted DHA oil. These fermentation process claims are not limited to any particular use of the DHA oil, i.e., they are relevant if the oils from the claimed processes are used in food or nonfood applications, such as human and animal foods, supplements, and pharmaceuticals. The Company believes that, on an overall basis, the patent as modified remains an important part of the Company's intellectual property portfolio and that the narrowing of the claims of the patent should not have any material adverse impact on the Company.

The patent was the subject of a challenge by Aventis Research and Technologies GmbH & Co. KG, and Nagase Limited. The Company believes that it is probable that at least one of the opponents of the patent will appeal the Opposition Division's decision. If an appeal is made, the Appeal Board hearing would be anticipated to oc
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ... "Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services ... Global Version" report to their offering. ... of molecular diagnostics and pharmacogenics hold the promise ... that is moving out of the national and ...
(Date:5/5/2015)... SAN FRANCISCO, Calif. , May 5, 2015 /PRNewswire/ ... the treatment of cancer, today announced that Sean ... at the Credit Suisse Antibody Day in ... Wednesday, May 6. Dr. McCarthy will present an overview ... immunotherapy and Probody drug conjugate programs. About ...
(Date:5/5/2015)... 5, 2015   Tocagen Inc. , a ... R. Parkinson , M.D., a venture partner at ... the board of directors of Tocagen. Dr. Parkinson ... oncology clinical development, including leading clinical activities at ... of the cancer therapeutics Gleevec®, Femara®, Zometa®, Kepivance® ...
(Date:5/5/2015)... 2015 GEA Pharma Systems, G-CON ... recipients of the INTERPHEX Exhibitor Awards for 2015 ... Portable, Continuous, Miniature and Modular (PCMM) platform. PCMM ... continuous processing equipment, smart control systems and PODs ... and inactive ingredients into bulk tablets. , ...
Breaking Biology Technology:Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3
... Calif., Jan. 7 Intradigm Corporation, a leading,developer ... that the company has closed the final tranche ... the $2.9 million tranche, with,existing investor, Lilly Ventures, ... the total Series B financing to $21.4 million. ...
... SEATTLE, Jan. 7 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... that,the NASDAQ Listing Qualifications Panel has granted CTI,s request ... NASDAQ Global Market to The NASDAQ,Capital Market, which will ... 8, 2009. CTI,s shares will continue to trade under ...
... Calif., Jan. 6 InterMune, Inc.,(Nasdaq: ITMN ... Executive,Officer and President of InterMune, will present at the ... January 15, 2009 at 1:00 p.m.,PST. , ... the presentation, investors and other,interested parties may log on ...
Cached Biology Technology:Intradigm Closes Final Tranche of $21.4 Million Series B Financing 2Intradigm Closes Final Tranche of $21.4 Million Series B Financing 3Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market 2Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market 3
(Date:3/31/2015)... , March 31, 2015   Guidepoint , a ... of the Post-Surgical Pain Management TRACKER, part of the ... usage trends in the medical device and therapeutics markets. ... data including treatment volumes, market share, and adoption rates ... associated with joint surgery. The Post-Surgical Pain ...
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ( ... Voice Biometrics - Global Strategic Business Report" report to their ... and Voice Biometrics in US$ Thousands by the following Segments: Face ... the US, Canada , Japan ... Middle East & Africa ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... A University of Houston partnership that helped Houston avoid the ... all over the state thanks to an $8.8 million grant ... The Texas Diesel Testing and Research Center at the ... a portable emission testing system and a heavy-duty engine dynamometer, ...
... news for chips lovers everywhere new research in SCIs ... pre-soaking potatoes in water before frying can reduce levels of ... when starch rich foods are cooked at high temperatures, such ... growing concern that acrylamide found in a wide range ...
... March 4 /PRNewswire-FirstCall/,-- Phoenix Technologies Ltd. (Nasdaq: ... ATML ) today announced the integration of ... and SecureCore,Pre-boot Authentication (PBA) products., (Logo: ... design effort between the two industry leaders,provides ...
Cached Biology News:State, UH teaming up to reduce (ob)noxious air emissions 2Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs 2Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs 3Phoenix Technologies and Atmel Collaborate to Create Next-Generation Security Solutions for PCs 4
EZ-DeWax is a one-step solution that simultanously removes paraffin from and rehydrates formalin-fixed, paraffin embedded tissue...
... dual-bay DNA Engine Dyad thermal cycler ... amplification (PCR). The chassis accommodates a ... heat-pump assemblies), which hold different types ... offers graphical programming with point-and-click navigation. ...
... Secondary Detection System is intended for use ... Antibody reagents, which contain rat and goat ... by light microscopy in paraffin-embedded tissues. The ... also be used with other rat or ...
... Leu-CMK FLISP Assay with SR-101 ... Em=620 nm) • Accurately measure serine ... or permeabilization • B-Bridge's FLISP Kits ... serine proteases (FLISPs) to measure chymotrypsin-like ...
Biology Products: